1 available, 1 completed, 1 recruiting, 1 unknown. 2 Phase 4, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Completed 1, Recruiting 1 |
| Not applicable | 1 | Unknown 1 |
Follow Cytochrome P-450 CYP2C9: new trials by email Literature Review of Cytochrome P-450 CYP2C9 trials Research Report on Cytochrome P-450 CYP2C9
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies Olutasidenib, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates - AML (Acute Myeloid Leukemia), Glioma | Phase 4 | Recruiting | Rigel Pharmaceuticals | 16 | 2026-02-23 | 2026-08-11 |
| Pharmacogenomics Applied to Chronic Pain Treatment in Primary Care Pharmacogenetic Testing, Pharmacist Consultation Note, Delayed pharmacogenetic testing - Chronic Pain | Not applicable | Unknown | Medstar Health Research Institute | 315 | 2020-12-02 | 2024-03-26 |
| Pharmacogenetic and Pharmacokinetics of Naproxen and Associated Naproxen-esomeprazole Naproxen, Naproxen-esomeprazole - Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome p450 CYP2C19 Variant | Phase 4 | Completed | University of Sao Paulo | 8 | 2017-03-01 | 2020-11-03 |
| Effect of Genes on Rosuvastatin Therapy for Hyperlipidemia rosuvastatin,fenofibrate, CYP2C9, UGT1A1, UGT1A3, OATP2, BCRP - Hyperlipidemia | Available | National Taiwan University Hospital | 2012-12-21 |
Cholangiocarcinoma (1) · Chronic Pain (1) · Disease (1) · Dyslipidemias (1) · Glioma (1) · Hyperlipidemias (1) · Leukemia, Myeloid, Acute (1) · Metabolic Syndrome (1) · Neoplasms (1)
Medstar Health Research Institute (1) · National Taiwan University Hospital (1) · Rigel Pharmaceuticals (1) · University of Sao Paulo (1)
United States (2) · Brazil (1)
Adriana M Calvo, PhD (1) · Max Smith, PharmD (1)